Stock A083790 CG INVITES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CG Invites Co., Ltd.

Equities

A083790

KR7083790006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
2,435 KRW -0.20% Intraday chart for CG Invites Co., Ltd. -4.70% -12.25%
May. 14 CG Invites Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 698,724 612,557 821,286 450,793 241,175 208,277
Enterprise Value (EV) 1 578,661 556,353 744,096 403,016 229,340 195,990
P/E ratio 93.5 x -15.9 x -78.7 x -28.5 x -10.1 x -4.2 x
Yield - - - - - -
Capitalization / Revenue 50.3 x 43.7 x 27.2 x 10.6 x 6.24 x 42.7 x
EV / Revenue 41.7 x 39.7 x 24.6 x 9.51 x 5.93 x 40.2 x
EV / EBITDA 192 x -63.8 x -141 x -105 x -10.9 x -6.78 x
EV / FCF -112 x -14.5 x 36.6 x -21.6 x -7.76 x 24.7 x
FCF Yield -0.9% -6.91% 2.73% -4.63% -12.9% 4.05%
Price to Book 3.8 x 4.12 x 3.85 x 2.15 x 1.28 x 1.46 x
Nbr of stocks (in thousands) 60,583 62,083 68,823 68,096 68,907 75,055
Reference price 2 11,533 9,867 11,933 6,620 3,500 2,775
Announcement Date 3/14/19 3/19/20 3/23/21 3/18/22 3/21/23 3/15/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 13,887 14,007 30,223 42,376 38,642 4,879
EBITDA 1 3,016 -8,714 -5,294 -3,851 -20,956 -28,920
EBIT 1 1,756 -10,560 -10,210 -6,846 -23,969 -32,119
Operating Margin 12.65% -75.39% -33.78% -16.16% -62.03% -658.37%
Earnings before Tax (EBT) 1 7,148 -37,725 -14,011 -15,617 -25,035 -51,152
Net income 1 6,908 -37,585 -9,838 -15,901 -23,869 -48,924
Net margin 49.74% -268.34% -32.55% -37.52% -61.77% -1,002.81%
EPS 2 123.3 -618.8 -151.6 -232.2 -345.0 -661.3
Free Cash Flow 1 -5,186 -38,459 20,341 -18,668 -29,538 7,942
FCF margin -37.34% -274.58% 67.3% -44.05% -76.44% 162.78%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/14/19 3/19/20 3/23/21 3/18/22 3/21/23 3/15/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 120,062 56,204 77,191 47,777 11,835 12,287
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -5,186 -38,459 20,341 -18,668 -29,538 7,942
ROE (net income / shareholders' equity) 5% -18.6% -6.76% -8.43% -11.9% -26.7%
ROA (Net income/ Total Assets) 0.58% -2.08% -1.83% -1.32% -4.57% -7.1%
Assets 1 1,184,226 1,811,257 536,627 1,207,620 522,262 689,366
Book Value Per Share 2 3,033 2,395 3,102 3,072 2,732 1,898
Cash Flow per Share 2 575.0 836.0 682.0 458.0 435.0 301.0
Capex 1 293 618 6,748 10,607 14,632 23,236
Capex / Sales 2.11% 4.41% 22.33% 25.03% 37.87% 476.27%
Announcement Date 3/14/19 3/19/20 3/23/21 3/18/22 3/21/23 3/15/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CG INVITES CO., LTD. Stock CG Invites Co., Ltd.
-12.25% 135M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.73% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.43% 240B
NOVARTIS AG Stock Novartis AG
+9.52% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.40% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A083790 Stock
  4. Financials CG Invites Co., Ltd.